"The current publication which follows our announcement from 07 September 2011, further supports Pluristem's finding that the combination of the Placenta as a rich cell source and our propriety 3D manufacturing platform may lead to new product and therapies for unmet needs and will increase the level of awareness for our technology in the medical community," stated Pluristem Chairman and CEO Zami Aberman.About Pluristem Therapeutics
Pluristem's Preclinical Results For Its PLX-RAD Cells Published In The Journal PLOS ONE
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.